{"id":"bb14bba9dfb1","type":"article","url":"https://hartvaat.nl/2025/01/01/medicamenteuze-therapie-bij-niet-obstructieve-hcm-nieuwe-perspectieven/","title":"Medicamenteuze therapie bij niet-obstructieve HCM: nieuwe perspectieven","title_en":"Drug Therapy in Nonobstructive Hypertrophic Cardiomyopathy: Out of the Darkness Into the Light","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","aficamten","answer-hf","bloeddrukbehandeling","bradycardie","cardiale-resynchronisatie","cardiomyopathie-gerichte-therapie","cardiorenal-behandelstrategie","diabetes-en-hart","farmaco-economie","gedilateerde-cardiomyopathie","hartrevalidatie","hypertrofische-cardiomyopathie","iaso-dcm","immunoadsorptie","laminopathie","mavacamten","myocardinfarct","niet-statine-therapie","obesitas","ouderen","summit-trial","supraventriculaire-tachycardie","vrouwen"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725104361?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725104361?dgcid=rss_sd_all","authors":["Martin S. Maron"],"significance":6,"published":"2026-03-24","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This JACC editorial discussed the therapeutic advances in nonobstructive hypertrophic cardiomyopathy, a subgroup previously lacking targeted treatment options, evaluating the potential of cardiac myosin inhibitors beyond obstruction relief.","created":"2026-07-03T10:32:38Z","updated":"2026-07-03T18:39:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Dit JACC-editorial bespreekt de therapeutische vooruitgang bij niet-obstructieve hypertrofische cardiomyopathie, een subgroep waarvoor tot nu toe weinig evidence-based behandelopties bestonden. De auteur schetst hoe nieuwe inzichten de klinische aanpak van deze patiënten fundamenteel kunnen veranderen.","abstract_original":"Publication date: 3 March 2026Source: JACC, Volume 87, Issue 8"}